- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | GeneDx Holdings Corp.: GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset | 59 | GlobeNewswire (Europe) | STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo... ► Artikel lesen | |
| 04.04. | GeneDx Holdings Corp.: GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 | 2 | GlobeNewswire (USA) | ||
| 14.03. | GeneDx Holdings Corp.: GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics | 1 | GlobeNewswire (USA) | ||
| 26.02. | GeneDx Holdings Corp.: GeneDx to Participate in 44th Annual Cowen Health Care Conference | 1 | GlobeNewswire (USA) | ||
| 23.02. | GeneDx Holdings Corp. - 10-K, Annual Report | - | SEC Filings | ||
| 21.02. | Earnings call: GeneDx posts revenue rise, eyes profitability by 2025 | 1 | Investing.com | ||
| 20.02. | GeneDx reports Q4 results | 1 | Seeking Alpha | ||
| 20.02. | GeneDx Holdings Corp.: GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 | 222 | GlobeNewswire (Europe) | Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins2... ► Artikel lesen | |
| 20.02. | GeneDx Holdings Corp. - 8-K, Current Report | - | SEC Filings | ||
| 19.02. | Earnings Preview: GeneDx Holdings | 1 | Benzinga.com | ||
| 01.02. | GeneDx Holdings Corp.: GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 | 2 | GlobeNewswire (USA) | ||
| 30.01. | Sema4.ai Raises $30.5M in Funding | 1 | FinSMEs | ||
| 30.01. | Sema4.ai: $30.5 Million Secured To Build Intelligent Agents For Helping Knowledge Workers | 1 | pulse2.com | ||
| 29.01. | AI startup Sema4.ai, led by former Cloudera CEO Rob Bearden, raises $30.5M | 1 | SiliconANGLE | ||
| 29.01. | Sema4.ai Secures $30.5 Million to Bring AI to Enterprise Work | 1 | PYMNTS.com | ||
| 24.01. | GeneDx Holdings Corp.: GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 08.01. | GeneDx Holdings stock soars after company forecasts upbeat Q4 guidance, reiterates profitability outlook | 1 | Seeking Alpha | ||
| 08.01. | GeneDx Holdings Corp.: GeneDx Announces Preliminary 2023 Financial Results | 221 | GlobeNewswire (Europe) | Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome... ► Artikel lesen | |
| 08.01. | GeneDx Holdings Corp. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.23 | GeneDx Holdings Corp.: GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy | 372 | GlobeNewswire (Europe) | STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be presented... ► Artikel lesen |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 36,760 | +2,00 % | Eckert & Ziegler gutes Q1 - reicht zumindest für Prognosebestätigung. Und Kursfeuerwerk. Eintagsfliege? | Eckert & Ziegler (ISIN: DE0005659700) - Anfang Januar noch beim Platow Brief als klarer KAUF eingestuft - liefert heute im Rahmen einer ad-hoc-Meldung einen vorläufigen Blick auf die Q1-Zahlen, die... ► Artikel lesen | |
| INTUITIVE SURGICAL | 346,50 | -0,39 % | Quartalszahlen: China sei Dank: Intuitive Surgical übertrifft Erwartungen, Aktie steigt! | © Foto: Frank Molter - picture allianceDie Aktie des Herstellers von Medizinrobotern Intuitive Surgical ist nach guten Quartalszahlen gefragt und steigt.Erholung in China ließ lange auf sich warten... ► Artikel lesen | |
| ROKU | 56,49 | -3,49 % | Netflix Keeps Crashing on Roku TV | ||
| BICO GROUP | 3,820 | -0,10 % | Bico Group Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| ATOSSA THERAPEUTICS | 1,446 | +1,69 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen | SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
| ASENSUS SURGICAL | 0,212 | -13,02 % | Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG | RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) ("Asensus" or the "Company"), a medical device company that is digitizing the interface... ► Artikel lesen | |
| QUIDELORTHO | 36,800 | -0,54 % | QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
| VERU | 1,206 | +5,98 % | Veru Inc.: Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 | ||
| TEMPEST THERAPEUTICS | 3,140 | -3,03 % | Tempest Therapeutics: Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications | TPST-1120, a first-in-class, oral, selective PPAR? antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data... ► Artikel lesen | |
| CENTENE | 70,59 | +0,07 % | Centene-Aktie legt um 0,84 Prozent zu (71,0929 €) | Im Plus liegt aktuell das Wertpapier von Centene . Das Papier kostete zuletzt 75,78 US-Dollar. Heute hat sich an der US-amerikanischen Börse die Centene-Aktie zwischenzeitlich um 0,84 Prozent verteuert.... ► Artikel lesen | |
| BONESUPPORT | 20,740 | +1,77 % | Bonesupport Holding AB publishes Q1 2024 Interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2024.
THE GROWTH JOURNEY CONTINUESJANUARY... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 1,500 | +0,67 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results | SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout... ► Artikel lesen | |
| LANTHEUS | 60,10 | -1,15 % | Lantheus Holdings, Inc.: Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer | BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight... ► Artikel lesen | |
| OMNICELL | 25,400 | 0,00 % | Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today... ► Artikel lesen |
GENEDX HOLDINGS CORP gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 11,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
